Swiss biotech Oculis has raised $21 million in a Series B round backed by investors including Novartis (NYSE:NVS) and Bay City Capital. The company is developing topical drugs for back-of-the-eye diseases, which are normally treated with painful injections directly into the eye. Get the full story at our sister site, Drug Delivery Business News.
Ophthalmalogical developer Oculis said today it closed a Series A round of financing to support its solubilizing nanoparticle drug delivery platform, currently being designed to deliver drugs to treat diabetic macular edema. The company did not disclose the amount raised in the round. The SNP platform is designed to “solve the limitations of available eye-drop […]